glp-1 for sleep apnea Will Drugs Disrupt the Market? GLP-1 for Sleep Apnea |

Sci Transl Med 9(404):eaan0972 Mitchell JL et al (2023) The effect of GLP-1RA exenatide on idiopathic intracranial hypertension: a randomized clinical trial

A status conference for these cases is slated for next week, with discussions expected to include planning for the upcoming Science Day and a status update for discovery

Some compounding pharmacies also offer sublingual (under-the-tongue) formulations, but these have not been extensively studied and the FDA has raised concerns about salt-form variations

Meanwhile, Eli Lilly, manufacturer of competing GLP-1s Mounjaro and Zepbound, is continuing to do pretty well

[DOI] [PubMed] [Google Scholar] 102.Pinto M., Brennan L., Diehl K., Lin S., Heacock S

Conversely, Lakshminarayanan Varadhan et al